Nebenwirkungen · Cerdelga
Cerdelga 21 mg hard capsules Cerdelga 84 mg hard capsules · Abschnitt 4.8 · PDF-Seite 8
HOS-130444 · Präparat HOS-096915
In the ELIKIDS paediatric study Cohort 1 (eliglustat monotherapy), the most common adverse reactions were dyspepsia (9.8%) and dry skin (3.6%). In Cohort 2 (eliglustat/imiglucerase combination therapy), the most common adverse reactions were headache, dyspepsia, gastritis, and fatigue (each experienced by 16.7% (1/6) of the patients). Of 57 enrolled patients, 53 (93%, 48/51 in Cohort 1) experienced at least one treatment-emergent adverse event (TEAE) with no meaningful difference by age group, gender, or GD type. No patients permanently discontinued treatment due to TEAE.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-27T15:21:00Z · SHA-256 1c727ba97e10c9a78b07345b037b7efc3b42bce5b1ed72eaf8881cd34d7be69a · Passage 89e6214a4b862325af89b05d61b86e64517c5432b793acadc12e600da582346d · Zeichen 1992–2570 im Abschnitt